je.st
news
Home
› Catalent Biologics And Cerenis Therapeutics Announce Phase III Trial Of CER-001 In Europe And North America Leveraging GPEx Cell Line Technology
Catalent Biologics And Cerenis Therapeutics Announce Phase III Trial Of CER-001 In Europe And North America Leveraging GPEx Cell Line Technology
2016-02-03 03:16:56| drugdiscoveryonline Home Page
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products, today announced that Cerenis Therapeutics has advanced its leading clinical candidate, CER-001, into Phase III clinical studies across Europe and North America
Tags: line
technology
north
iii
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||